BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KK2845 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KK2845\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06812104-3119@assetmemo.bio
DTSTAMP:20261121T005402Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:KK2845: Phase 1 readout est. (NCT06812104)
DESCRIPTION:KK2845\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase I Clin
 ical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid
  Leukemia and Other Hematologic Malignancies.\nEstimated primary completio
 n: 30 November 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 kk2845#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06812104
URL:https://assetmemo.bio/drug/kk2845#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
